

# Gaetano Bertino

## List of Publications by Citations

**Source:** <https://exaly.com/author-pdf/4577302/gaetano-bertino-publications-by-citations.pdf>

**Version:** 2024-04-27

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

86  
papers

2,204  
citations

25  
h-index

45  
g-index

90  
ext. papers

2,582  
ext. citations

3.3  
avg. IF

4.39  
L-index

#	Paper	IF	Citations
86	Incidence of Hepatocellular Carcinoma in Patients With HCV-Associated Cirrhosis Treated With Direct-Acting Antiviral Agents. <i>Gastroenterology</i> , <b>2018</b> , 155, 411-421.e4	13.3	201
85	Terlipressin and albumin in patients with cirrhosis and type I hepatorenal syndrome. <i>Digestive Diseases and Sciences</i> , <b>2008</b> , 53, 830-5	4	144
84	Potential role of probiotics on colorectal cancer prevention. <i>BMC Surgery</i> , <b>2012</b> , 12 Suppl 1, S35	2.3	138
83	Hepatocellular carcinoma serum markers. <i>Seminars in Oncology</i> , <b>2012</b> , 39, 410-33	5.5	128
82	Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct-acting antivirals? A prospective multicentre study. <i>Alimentary Pharmacology and Therapeutics</i> , <b>2017</b> , 46, 688-695	6.1	104
81	Gut microbiota in alcoholic liver disease: pathogenetic role and therapeutic perspectives. <i>World Journal of Gastroenterology</i> , <b>2014</b> , 20, 16639-48	5.6	90
80	What is changing in indications and treatment of hepatic hemangiomas. A review. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 327-339	3.1	87
79	Direct-acting antivirals after successful treatment of early hepatocellular carcinoma improve survival in HCV-cirrhotic patients. <i>Journal of Hepatology</i> , <b>2019</b> , 71, 265-273	13.4	80
78	Hepatocellular carcinoma: novel molecular targets in carcinogenesis for future therapies. <i>BioMed Research International</i> , <b>2014</b> , 2014, 203693	3	58
77	Chronic hepatitis C: This and the new era of treatment. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 92-106	3.4	57
76	Hepatocellular carcinoma and the risk of occupational exposure. <i>World Journal of Hepatology</i> , <b>2016</b> , 8, 573-90	3.4	52
75	Serum Markers of Intrahepatic Cholangiocarcinoma. <i>Disease Markers</i> , <b>2013</b> , 34, 219-228	3.2	48
74	Greater severity of new onset asthma in allergic subjects who smoke: a 10-year longitudinal study. <i>Respiratory Research</i> , <b>2011</b> , 12, 16	7.3	48
73	Prognostic and diagnostic value of des-β-carboxy prothrombin in liver cancer. <i>Drug News and Perspectives</i> , <b>2010</b> , 23, 498-508		48
72	Diagnostic and prognostic value of alpha-fetoprotein, des-β-carboxy prothrombin and squamous cell carcinoma antigen immunoglobulin M complexes in hepatocellular carcinoma. <i>Minerva Medica</i> , <b>2011</b> , 102, 363-71	2.2	46
71	Effect of pre- and post-treatment αfetoprotein levels and tumor size on survival of patients with hepatocellular carcinoma treated by resection, transarterial chemoembolization or radiofrequency ablation: a retrospective study. <i>BMC Surgery</i> , <b>2014</b> , 14, 40	2.3	44
70	What is changing in indications and treatment of hepatic hemangiomas. A review. <i>Annals of Hepatology</i> , <b>2014</b> , 13, 327-39	3.1	44

69	Systemic therapies in hepatocellular carcinoma: present and future. <i>Future Oncology</i> , <b>2013</b> , 9, 1533-48	3.6	38
68	Serum markers of intrahepatic cholangiocarcinoma. <i>Disease Markers</i> , <b>2013</b> , 34, 219-28	3.2	35
67	L-carnitine supplementation improves hematological pattern in patients affected by HCV treated with Peg interferon- $\beta$ plus ribavirin. <i>World Journal of Gastroenterology</i> , <b>2011</b> , 17, 4414-20	5.6	34
66	Circulating endothelial-coagulative activation markers after smoking cessation: a 12-month observational study. <i>European Journal of Clinical Investigation</i> , <b>2011</b> , 41, 616-26	4.6	31
65	Anorectal mucosal melanoma. <i>Oncotarget</i> , <b>2018</b> , 9, 8785-8800	3.3	31
64	A multidisciplinary therapeutic approach for reducing the risk of psychiatric side effects in patients with chronic hepatitis C treated with pegylated interferon $\beta$ and ribavirin. <i>Journal of Clinical Gastroenterology</i> , <b>2010</b> , 44, e210-7	3	29
63	Laparoscopic Reversal of Hartmann's Procedure: State of the Art 20 Years after the First Reported Case. <i>Gastroenterology Research and Practice</i> , <b>2014</b> , 2014, 530140	2	26
62	Elevated serum levels of Chromogranin A in hepatocellular carcinoma. <i>BMC Surgery</i> , <b>2012</b> , 12 Suppl 1, S7	2.3	26
61	Resveratrol in Patients with Minimal Hepatic Encephalopathy. <i>Nutrients</i> , <b>2018</b> , 10,	6.7	25
60	Carbohydrate 19.9 antigen serum levels in liver disease. <i>BioMed Research International</i> , <b>2013</b> , 2013, 531640	3.4	25
59	Psychiatric symptoms induced by antiviral therapy in chronic hepatitis C: comparison between interferon-alpha-2a and interferon-alpha-2b. <i>Clinical Drug Investigation</i> , <b>2006</b> , 26, 655-62	3.2	25
58	The supplementation of acetyl-L-carnitine decreases fatigue and increases quality of life in patients with hepatitis C treated with pegylated interferon- $\beta$ plus ribavirin. <i>Journal of Interferon and Cytokine Research</i> , <b>2011</b> , 31, 653-9	3.5	24
57	Giant cavernous liver hemangiomas: is it the time to change the size categories?. <i>Hepatobiliary and Pancreatic Diseases International</i> , <b>2016</b> , 15, 21-9	2.1	24
56	Is Transient Elastography Needed for Noninvasive Assessment of High-Risk Varices? The REAL Experience. <i>American Journal of Gastroenterology</i> , <b>2019</b> , 114, 1275-1282	0.7	23
55	The immune system in hepatocellular carcinoma and potential new immunotherapeutic strategies. <i>BioMed Research International</i> , <b>2015</b> , 2015, 731469	3	22
54	Epoetin alpha improves the response to antiviral treatment in HCV-related chronic hepatitis. <i>European Journal of Clinical Pharmacology</i> , <b>2010</b> , 66, 1055-63	2.8	20
53	Rosuvastatin reduces nonalcoholic fatty liver disease in patients with chronic hepatitis C treated with Interferon and ribavirin: Rosuvastatin reduces NAFLD in HCV patients. <i>Hepatitis Monthly</i> , <b>2011</b> , 11, 92-8	1.8	20
52	Acetyl-L-Carnitine Supplementation During HCV Therapy With Pegylated Interferon- $\beta$ Plus Ribavirin: Effect on Work Performance; A Randomized Clinical Trial. <i>Hepatitis Monthly</i> , <b>2014</b> , 14, e11608	1.8	19

51	Liver immunolocalization and plasma levels of MMP-9 in non-alcoholic steatohepatitis (NASH) and hepatitis C infection. <i>Acta Histochemica</i> , <b>2010</b> , 112, 474-81	2	18
50	A study about mechanisms of des-gamma-carboxy prothrombinS production in hepatocellular carcinoma. <i>Panminerva Medica</i> , <b>2008</b> , 50, 221-6	2	18
49	Hepatitis C Virus Infection in Children and Pregnant Women: An Updated Review of the Literature on Screening and Treatments. <i>AJP Reports</i> , <b>2020</b> , 10, e121-e127	1.2	16
48	Resveratrol in Hepatitis C Patients Treated with Pegylated-Interferon- $\alpha$ and Ribavirin Reduces Sleep Disturbance. <i>Nutrients</i> , <b>2017</b> , 9,	6.7	15
47	Silybin supplementation during HCV therapy with pegylated interferon- $\alpha$ plus ribavirin reduces depression and anxiety and increases work ability. <i>BMC Psychiatry</i> , <b>2016</b> , 16, 398	4.2	14
46	Silybin-vitamin E-phospholipids complex reduces liver fibrosis in patients with chronic hepatitis C treated with pegylated interferon $\alpha$ and ribavirin. <i>American Journal of Translational Research (discontinued)</i> , <b>2015</b> , 7, 2510-8	3	13
45	Current practice of chronic hepatitis B treatment in Southern Italy. <i>European Journal of Internal Medicine</i> , <b>2012</b> , 23, e124-7	3.9	12
44	D-dimer plasmatic levels as a marker for diagnosis and prognosis of hepatocellular carcinoma patients with portal vein thrombosis. <i>Clinical and Experimental Gastroenterology</i> , <b>2018</b> , 11, 373-380	3.1	12
43	Rare benign tumors of the liver: still rare?. <i>Journal of Gastrointestinal Cancer</i> , <b>2014</b> , 45, 202-17	1.6	11
42	Persistent increase in alpha-fetoprotein level in a patient without underlying liver disease who underwent curative resection of hepatocellular carcinoma. A case report and review of the literature. <i>World Journal of Surgical Oncology</i> , <b>2012</b> , 10, 79	3.4	11
41	Reduction of volumetric bone mineral density in postmenopausal women with hepatitis C virus-correlated chronic liver disease: a peripheral quantitative computed tomography (pQCT) study. <i>European Journal of Internal Medicine</i> , <b>2012</b> , 23, 656-60	3.9	10
40	Endozepine-4 levels are increased in hepatic coma. <i>World Journal of Gastroenterology</i> , <b>2015</b> , 21, 9103-105.6	10.6	10
39	Real-world experience with obeticholic acid in patients with primary biliary cholangitis. <i>JHEP Reports</i> , <b>2021</b> , 3, 100248	10.3	10
38	Evaluation of health status in patients with hepatitis c treated with and without interferon. <i>Health and Quality of Life Outcomes</i> , <b>2018</b> , 16, 17	3	9
37	Carotid intima-media thickness and liver histology in hemodialysis patients with nonalcoholic Fatty liver disease. <i>International Journal of Angiology</i> , <b>2011</b> , 20, 149-56	1.1	9
36	Relationship between circulating interleukin-10 and histological features in patients with chronic C hepatitis. <i>Annals of Saudi Medicine</i> , <b>2011</b> , 31, 360-4	1.6	8
35	Meaning of elevated CA 19-9 serum levels in chronic hepatitis and HCV-related cirrhosis. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2007</b> , 53, 305-9	1.6	8
34	Altered pattern of circulating matrix metalloproteinases -2,- 9 and tissue inhibitor of metalloproteinase-2 in patients with HCV-related chronic hepatitis. Relationship to histological features. <i>Panminerva Medica</i> , <b>2009</b> , 51, 191-6	2	8

33	Hepatitis C virus eradication by direct antiviral agents improves glucose tolerance and reduces post-load insulin resistance in nondiabetic patients with genotype 1. <i>Liver International</i> , <b>2018</b> , 38, 1206-1211	7.9	7
32	Carcinoembryonic Antigen Serum Levels in Nonmelanoma Skin Cancer. <i>Biomedicines</i> , <b>2018</b> , 6,	4.8	7
31	A lethal complication after transarterial chemoembolization with drug-eluting beads for hepatocellular carcinoma. <i>Case Reports in Surgery</i> , <b>2015</b> , 2015, 873601	0.5	6
30	Hepatocellular carcinoma: present and future. <i>Chinese Clinical Oncology</i> , <b>2012</b> , 1, 14	2.3	6
29	Hepatocellular carcinoma markers in the omics era: the glycomic analysis. <i>Hepatobiliary Surgery and Nutrition</i> , <b>2014</b> , 3, 407-9	2.1	6
28	Some patients with HCC have abnormal des-gamma-carboxy prothrombin and alpha-fetoprotein levels. <i>Panminerva Medica</i> , <b>2009</b> , 51, 133-4	2	6
27	Rate of non-response to ursodeoxycholic acid in a large real-world cohort of primary biliary cholangitis patients in Italy. <i>Scandinavian Journal of Gastroenterology</i> , <b>2019</b> , 54, 1274-1282	2.4	5
26	Genotype-phenotype variable correlation in Wilson disease: clinical history of two sisters with the similar genotype. <i>BMC Medical Genetics</i> , <b>2020</b> , 21, 128	2.1	5
25	Emerging hepatic syndromes: pathophysiology, diagnosis and treatment. <i>Internal and Emergency Medicine</i> , <b>2016</b> , 11, 905-16	3.7	5
24	In chronic viral hepatitis without malignancy, abnormal serum carbohydrate 19-9 antigen levels are associated with liver disease severity and are related to different viral aetiology. <i>Digestive and Liver Disease</i> , <b>2010</b> , 42, 458-9	3.3	5
23	Individualized treatment of genotype 1 naïve patients: an Italian multicenter field practice experience. <i>PLoS ONE</i> , <b>2014</b> , 9, e110284	3.7	5
22	Responsibility of hepatitis C virus in the development of hepatocellular carcinoma: From molecular alterations to possible solutions. <i>World Journal of Hepatology</i> , <b>2018</b> , 10, 448-451	3.4	5
21	Circulating erythropoietin in microalbuminuric type 2 diabetic patients with normal renal function: a pilot study. <i>Journal of Diabetes and Its Complications</i> , <b>2006</b> , 20, 376-9	3.2	4
20	Carnitine Serum Levels in Frail Older Subjects. <i>Nutrients</i> , <b>2020</b> , 12,	6.7	4
19	Obesity and related diseases: an epidemiologic study in eastern Sicily. <i>Minerva Gastroenterologica E Dietologica</i> , <b>2006</b> , 52, 379-85	1.6	4
18	Homocysteine Serum Levels as Prognostic Marker of Hepatocellular Carcinoma with Portal Vein Thrombosis. <i>Current Molecular Medicine</i> , <b>2019</b> , 19, 532-538	2.5	3
17	Liver and cardiovascular mortality after hepatitis C virus eradication by DAA: Data from RESIST-HCV cohort. <i>Journal of Viral Hepatitis</i> , <b>2021</b> , 28, 1190-1199	3.4	3
16	Blood homocysteine levels are increased in hepatocellular carcinoma patients with portal vein thrombosis. A single centre retrospective cohort study. <i>International Journal of Surgery Open</i> , <b>2018</b> , 15, 60-65	0.9	3

15	High Carbohydrate 19-9 Antigen Serum Levels in Patients with Nonmelanoma Skin Cancer and Primary Occult Cancer. <i>Biomedicines</i> , <b>2020</b> , 8,	4.8	2
14	Intraoperative identification of biliocystic communication could be the key to avoiding postoperative complications independent of the adopted surgical technique to treat hydatid cysts. <i>World Journal of Surgery</i> , <b>2015</b> , 39, 550-1	3.3	1
13	Job performance in chronic hepatitis C virus patients treated with pegylated interferon- $\alpha$ b plus ribavirin: an observational study. <i>Translational Medicine Communications</i> , <b>2017</b> , 2,	4	1
12	Carotid intima-media thickness and liver histology in hemodialysis patients with nonalcoholic fatty liver disease. <i>International Journal of Angiology</i> , <b>2010</b> , 19, e132-e137	1.1	1
11	Aberrant sialylation in a patient with a variant and liver adenomatosis. <i>IScience</i> , <b>2021</b> , 24, 102323	6.1	1
10	Improvement of health-related quality of life and psychological well-being after HCV eradication with direct-acting antiviral agents. Real life setting data of an Italian cohort valued by Hepatitis Quality of Life Questionnaire (HQLQv2). <i>Anesthesia, Intensive Care and Pain in Neonates and Children</i> , <b>2020</b> , 6, 8152	2.1	1
9	Telbivudine on-treatment HBsAg loss in naive HBeAg negative chronic hepatitis B: a case report and brief review of the literature. <i>Clinica Terapeutica</i> , <b>2012</b> , 163, e429-34	1	1
8	Serum Folate deficiency in HCV related Hepatocellular Carcinoma.. <i>Scientific Reports</i> , <b>2022</b> , 12, 5025	4.9	1
7	Respiratory and Cardiovascular Health Effects of e-Cigarette Substitution: Protocol for Two Living Systematic Reviews. <i>JMIR Research Protocols</i> , <b>2021</b> , 10, e29084	2	0
6	What are the True Advantages of Devices for Hepatic Parenchymal Transection in Open Surgery?. <i>World Journal of Surgery</i> , <b>2015</b> , 39, 3028-9	3.3	
5	Folate levels in hepatocellular carcinoma patients with portal vein thrombosis. <i>BMC Gastroenterology</i> , <b>2020</b> , 20, 375	3	
4	Totally Implantable Venous Access Devices: Efforts Are Needed to Standardize Procedures to Avoid Complications. <i>World Journal of Surgery</i> , <b>2016</b> , 40, 1781-2	3.3	
3	Does follow-up offer the best quality of life for patients affected by so-called giantS haemangiomas of the liver?. <i>Hpb</i> , <b>2015</b> , 17, 1155	3.8	
2	Delta infection in eastern Sicily. <i>European Journal of Epidemiology</i> , <b>1987</b> , 3, 386-9	12.1	
1	Commentary on "Insertion of Totally Implantable Central Venous Access Devices by Surgeons" - What Is the Role of Surgeons When Implanting a Totally Implantable Venous Access Device to Prevent Immediate Complications?. <i>Annals of Coloproctology</i> , <b>2015</b> , 31, 163-4	1.9	